Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest investor presentation

Latest investor presentation

Latest clinical presentation
Latest quarterly earnings
Annual report

Annual report

Latest publications, posters & presentations

Our research

Global ticker
NASDAQNVAX
Latest press releases Events & presentation Reports & financials SEC filings Stock details & analyst coverage

SEC

Access filings by selecting the date range and type using the drop-down menus.

NASDAQNVAX
YearTrailing 12-monthsCalendar year 2023Calendar year 2022Calendar year 2021Calendar year 2020Calendar year 2019Calendar year 2018Calendar year 2017Calendar year 2016Calendar year 2015Calendar year 2014Calendar year 2013Calendar year 2012Calendar year 2011Calendar year 2010Calendar year 2009Calendar year 2008Calendar year 2007Calendar year 2006Calendar year 2005Calendar year 2004Calendar year 2003Calendar year 2002Calendar year 2001Calendar year 2000Calendar year 1999Calendar year 1998Calendar year 1997Calendar year 1996
TypeAll filingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
8-KReport of unscheduled material events or corporate eventNov 19, 1998Open Report of unscheduled material events or corporate event in HTML.Open Report of unscheduled material events or corporate event in DOC file.Open Report of unscheduled material events or corporate event in PDF file.Open Report of unscheduled material events or corporate event in XLS file.
10-QQuarterly report which provides a continuing view of a company's financial positionNov 16, 1998Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
10-QQuarterly report which provides a continuing view of a company's financial positionAug 13, 1998Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
10-QQuarterly report which provides a continuing view of a company's financial positionMay 13, 1998Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 10, 1998Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
10-K/AAmendment to a previously filed 10-KApr 6, 1998Open Amendment to a previously filed 10-K in HTML.Open Amendment to a previously filed 10-K in DOC file.Open Amendment to a previously filed 10-K in PDF file.Open Amendment to a previously filed 10-K in XLS file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 31, 1998Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.
PRER14AProxy soliciting materials. Revised preliminary materialMar 30, 1998Open Proxy soliciting materials. Revised preliminary material in HTML.Open Proxy soliciting materials. Revised preliminary material in DOC file.Open Proxy soliciting materials. Revised preliminary material in PDF file.Open Proxy soliciting materials. Revised preliminary material in XLS file.
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteMar 18, 1998Open A preliminary proxy statement providing notification matters to be brought to a vote in HTML.Open A preliminary proxy statement providing notification matters to be brought to a vote in DOC file.Open A preliminary proxy statement providing notification matters to be brought to a vote in PDF file.Open A preliminary proxy statement providing notification matters to be brought to a vote in XLS file.
S-3Simplified registration formFeb 17, 1998Open Simplified registration form in HTML.Open Simplified registration form in DOC file.Open Simplified registration form in PDF file.Open Simplified registration form in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.